Key result
In a real-world Indian outpatient setting, moxonidine was prescribed to 4.54% of hypertensive patients, primarily for resistant hypertension or intolerance to first-line drugs.
Observational (n=990)
No
In real-world Indian practice, moxonidine is used in about 4.5% of hypertensive patients, primarily for resistant hypertension or intolerance to first-line agents, highlighting a gap in current guidelines.
Answers are grounded in this paper and cite their sources.
Observational Indian data indicate selective moxonidine use in resistant hypertension; leaves open its comparative effectiveness and guideline role.
OBJECTIVE: The primary objective of this study was to assess the use of moxonidine, a centrally acting anti-hypertensive agent in real world practice. MATERIAL AND METHODS: Patients who attended out-patients clinic with diagnosis of hypertension were enrolled in the study. Demographics with co-morbid illnesses of all patients were recorded. Patient's prescriptions were recorded and anti-hypertensive medications were also analysed. RESULTS: A total of 990 patients were eligible during the study period. Moxonidine was used in 4.54% of patients. Two groups could be identified in moxonidine users - one Group with resistant hypertension (30 patients, 3.03% of total, 66.66% of moxonidine users) on multiple drugs to control BP and another Group with intolerance to conventional, first line drugs (15 patients 1.51% of total, 33.33% of moxonidine users). Moxonidine was not used in newly diagnosed hypertension cases. Resistant hypertension and renal failure predicted the use of moxonidine. Majority of drug used was as per current guidelines. CONCLUSIONS: Our study results reflected real world practice of current anti-hypertensive therapy. Patients generally receive medications in accordance with current recommendations and guidelines. Small but significant proportion of patients may require use of drugs like moxonidine to control high BP. Guidelines need to incorporate these real world practices.
No takes yet. Share an insight, caveat, or question.
Sagarad et al. (2013) conducted an observational in Hypertension (n=990). Moxonidine was evaluated on Proportion of patients prescribed moxonidine. In a real-world Indian outpatient setting, moxonidine was prescribed to 4.54% of hypertensive patients, primarily for resistant hypertension or intolerance to first-line drugs.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: